Development of lead compounds as a SHP2 degrader for the treatment of KRAS mutant cancer

Elgen Therapeutic Inc.

Elgen THERAPEUTICS

ONCOLOGY | **Lead**

Product Type	Targeted Protein Degradation
Indication	KRAS mutant cancer (PDAC, NSCLC, CRC)
Target	SHP2
MoA(Mechanism of Action)	• SHP2 PROTAC degraders lead to fast and efficient SHP2 degradation in a proteasome-dependent mechanism. • Degradation of SHP2 is effective in targeting both upstream (RTK-driven) and downstream (RAS-GTP dependent) mutations in the RAS-MAPK pathway. • Degradation of SHP2 blocks RAS/MAPK signaling and functions as pan-KRAS inhibitor, covering diverse KRAS mutations. • SHP2 degraders may prevent feedback reactivation of the RAS/MAPK pathway when used in combination with KRAS/RTK inhibitors.
Competitiveness	• Elgen's potent SHP2 PROTAC degrader can block the RTK/RAS/MAPK signaling pathways and inhibit the growth and proliferation of tumor cells driven by SHP2 and/or with KRAS mutations. • PROTAC-induced SHP2 degradation is able to destroy all of it's catalytic and non-catalytic functions, it induces pERK inactivation and cell growth inhibition. • Combination of SHP2 degrader and KRAS/RTK inhibitor can exhibit synergistic efficacy and reduce toxicity.
Development Stage	Lead
Route of Administration	Intravenous

Any unauthorized distribution or reproduction of this material is strictly prohibited.